Homovanillate Test · Dried Urine

Your body breaks down dopamine, the brain chemical tied to movement, motivation, and reward, into a stable waste product called homovanillate. Measuring it in urine offers a non-invasive look at how actively your dopamine system is turning over.

This is a research-grade marker, not a routine clinical test for healthy adults. Its strongest established uses are in pediatric cancer screening and in studying neurological and psychiatric conditions, but it can also offer exploratory insight into how stress, toxin exposure, and certain neurological processes are affecting your dopamine chemistry.

What This Biomarker Reflects

HVA (homovanillic acid, the chemical name for homovanillate) is the main end-product of dopamine breakdown. After dopamine is released from nerve cells or produced by other catecholamine-making cells in the body, enzymes convert it through several steps into HVA, which then enters the bloodstream and is filtered out through the kidneys into urine.

Because HVA reflects the activity of dopamine breakdown rather than dopamine itself, the level you measure is a downstream signal of dopamine synthesis, release, and metabolism across both the brain and peripheral nervous system. Some HVA in urine comes from brain dopamine activity, but a substantial fraction reflects dopamine produced outside the brain by sympathetic nerves and other tissues.

Neuroblastoma and Catecholamine-Producing Tumors

The most established clinical use of urinary HVA is in diagnosing and monitoring neuroblastoma, a tumor of catecholamine-producing nerve tissue that occurs mainly in young children. These tumors release dopamine and related molecules that get broken down into HVA, so urinary HVA rises when the tumor is active.

Adding HVA to a broader urinary catecholamine panel raises diagnostic sensitivity for neuroblastoma to roughly 95 out of 100 cases when combined with other metabolites, compared to lower sensitivity with HVA and vanillylmandelic acid alone. In children with localized disease, the ratio of vanillylmandelic acid to HVA also carries prognostic information, with lower ratios linked to worse outcomes.

This use case is almost entirely pediatric, but it is the reason HVA testing exists as a clinical assay at all. If you are an adult considering this test, the neuroblastoma context is helpful for understanding what the lab is measuring, even though it is not why you would order it.

Parkinson Disease and Dopamine-Related Neurological Conditions

In Parkinson disease and related conditions like multiple system atrophy, dopamine-producing neurons progressively die off. Studies measuring HVA in cerebrospinal fluid (the fluid around the brain and spinal cord, sampled by spinal tap, not urine) show decreased levels, consistent with loss of brain dopamine activity.

Urinary HVA in Parkinson disease is more complex. People on levodopa therapy often show higher urinary HVA, reflecting the increased dopamine turnover that the medication produces, and urinary HVA has been studied as a potential marker of treatment response and disease state. One study did find that HVA in cerebrospinal fluid changed little over 24 months in mildly affected, untreated Parkinson patients, suggesting it is not a reliable marker of disease progression on its own.

In dementia with Lewy bodies, cerebrospinal fluid HVA combined with another monoamine metabolite has shown high accuracy in distinguishing this condition from Alzheimer disease in autopsy-confirmed cases. Most of this evidence comes from cerebrospinal fluid measurements rather than urine, and the two are not interchangeable.

Mental Health and Stress

A study of 100 workers found that those reporting high occupational stress had significantly lower urinary HVA and dopamine compared to lower-stress workers, suggesting reduced dopaminergic activity under chronic stress. This points toward urinary HVA as a possible objective indicator of how the dopamine system is responding to long-term stress, though the science here is still exploratory.

In psychiatric conditions, the picture is mixed. Plasma HVA has been studied as a marker for psychosis response and schizophrenia, but in major depression, blood HVA shows no consistent relationship with symptom severity. A meta-analysis found only low-level evidence for reduced cerebrospinal fluid HVA in depression compared to healthy controls. For most psychiatric uses, HVA is a research tool, not a clinical decision-maker.

Toxin Exposure

Chronic occupational exposure to certain industrial chemicals can shift urinary HVA. Workers exposed to carbon disulfide showed dose-related reductions in urinary HVA and vanillylmandelic acid, consistent with disturbance of catecholamine metabolism. Arsenic exposure has also been linked to changes in HVA and other neurotransmitter markers, with neurometabolite patterns predicting risk of cognitive decline.

What this means for you: if you have ongoing exposure to industrial solvents, heavy metals, or other neurotoxic chemicals through work or environment, abnormal HVA can be one of several signals worth investigating further alongside specific toxin testing.

Hypothalamic Dysfunction and Severe Obesity

In patients with craniopharyngioma (a tumor that damages the hypothalamus, the brain region controlling appetite and sympathetic outflow), lower urinary HVA was linked to higher body mass index and reduced physical activity. The interpretation is that hypothalamic damage reduces sympathetic nervous system activity, which lowers catecholamine turnover and the resulting HVA.

This is a niche finding tied to a specific medical condition, but it illustrates a broader principle: urinary HVA reflects how active your sympathetic and dopaminergic systems are, and conditions that suppress those systems can show up as lower levels.

Why Higher and Lower Both Need Interpretation

This is not a simple higher-is-bad or lower-is-bad marker. HVA can be markedly elevated in catecholamine-producing tumors, modestly elevated in dopamine-active states or during levodopa treatment, and lower in chronic stress, hypothalamic damage, neurodegeneration, or certain toxin exposures. Two people with abnormal HVA can have completely different underlying biology.

Think of HVA as a phenotype indicator rather than a good-number bad-number test. Its value is in showing whether your dopamine metabolism looks unusual in some direction, which then tells you where to look next. The clinical meaning of any single result depends entirely on the context: what symptoms you have, what medications you take, what your other labs show, and what direction the abnormality goes.

Reference Ranges

There are no universally standardized adult reference ranges for urinary HVA aimed at preventive use. Published values come mostly from neuroblastoma diagnostic work in children and from research cohorts using different assays and reporting conventions. The most rigorous pediatric reference data come from a study of 1,533 children that established continuous reference intervals for cerebrospinal fluid HVA by age. Adult urinary HVA values are typically reported in micrograms per milligram of creatinine to control for urine concentration.

Because there is no consensus adult cutpoint and assay methods vary across labs, treat any single value as orientation, not a clinical threshold. Compare your results within the same lab and assay over time, and ask the lab providing your test which reference range they apply and what population it is based on.

Tracking Your Trend

For an exploratory marker like HVA, a single value is rarely as informative as a trend. Urinary HVA can shift with stress, diet, medications, and acute conditions, so one out-of-range result is not a verdict. Establishing a baseline and retesting under similar conditions gives you something meaningful to compare against.

A reasonable approach: get a baseline reading, retest in 3 to 6 months if you are making targeted lifestyle changes or have started or stopped a relevant medication, and then at least annually if you want ongoing monitoring. If your first result is markedly abnormal, retest within a few weeks to confirm before drawing conclusions, since transient factors can shift a single urine reading.

When Results Can Be Misleading

Several factors can shift urinary HVA without indicating disease:

• Diet: ingesting foods high in catecholamine precursors can artifactually elevate urinary HVA. Olive consumption has been documented to cause false suspicion of relapsed neuroblastoma. Vanilla, bananas, and certain fruits and nuts can also affect catecholamine metabolite testing.
• Levodopa and related dopamine medications: these genuinely raise dopamine turnover and elevate HVA, but the elevation reflects the drug, not a tumor or other pathology.
• Acute stress, exercise, or illness in the days before testing: catecholamine release fluctuates with sympathetic activity, and a single sample can capture a transient spike or dip.
• Ibuprofen metabolites: have been shown to interfere with the laboratory analysis of urinary HVA and can distort results.

For best accuracy, follow your lab's pre-test instructions on food and medication restrictions, collect the sample under typical conditions rather than after an unusual day, and avoid testing during acute illness.

What to Do With an Abnormal Result

An unexpected HVA result on its own is rarely a diagnosis. The decision pathway depends on the direction and context.

If your HVA is markedly elevated, especially with other catecholamine metabolites also elevated, the workup typically involves repeat testing under controlled conditions and a broader urinary catecholamine panel (including vanillylmandelic acid and metanephrines) to rule out a catecholamine-producing tumor. This is uncommon in adults but the most consequential finding to exclude.

If your HVA is low and you have neurological symptoms suggestive of Parkinson disease or related conditions, a neurologist's evaluation is the appropriate next step, since the diagnostic workup centers on clinical examination and brain imaging rather than urinary markers.

If your HVA is mildly abnormal without other concerning findings, the most useful next step is to repeat the test after addressing pre-test confounders (diet, medications, recent stress) and to interpret it alongside your overall clinical picture, including thyroid function, adrenal markers, heavy metal screening if exposure is plausible, and stress and sleep assessment.